SLXN (Silexion Therapeutics) Property, Plant and Equipment: $0.37 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SLXN Silexion Therapeutics Corp SLXN
13 GF Score
Price $0.37
! 1 Warning Sign
View Full Analysis

What is Silexion Therapeutics Property, Plant and Equipment?

Silexion Therapeutics SLXN +0.73% 13 Property, Plant and Equipment is $0.37 Mil as of Jun. 2026. GuruFocus rates SLXN with a GF Score™ of 13/100. The stock has 1 warning sign investors should review.

Silexion Therapeutics's quarterly net PPE declined from Dec. 2025 ($0.44 Mil) to Mar. 2026 ($0.40 Mil) and declined from Mar. 2026 ($0.40 Mil) to Jun. 2026 ($0.37 Mil).

Silexion Therapeutics's annual net PPE increased from Dec. 2023 ($0.25 Mil) to Dec. 2024 ($0.56 Mil) but then declined from Dec. 2024 ($0.56 Mil) to Dec. 2025 ($0.44 Mil).


Silexion Therapeutics  (NAS:SLXN) Property, Plant and Equipment Explanation

A company with durable competitive advantage doesn't need to constantly upgrade its equipment to stay competitive. The company replaces when it wears out. On the other hand, a company without any advantages must replace to keep pace.

Difference between a company with a moat and one without is that the company with the competitive advantage finances new equipment through internal cash flows, whereas the no advantage company requires debt to finance.

Producing a consistent product that doesn't change equates to consistent profits. There is no need to upgrade plants which frees up cash for other ventures. Think Coca Cola, Johnson & Johnson etc.


Silexion Therapeutics Property, Plant and Equipment Related Terms


Silexion Therapeutics Property, Plant and Equipment Historical Data

* Premium members only.

The historical data trend for Silexion Therapeutics's Property, Plant and Equipment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Silexion Therapeutics Property, Plant and Equipment Chart

Silexion Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Property, Plant and Equipment
0.46 0.25 0.56 0.44

Silexion Therapeutics Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Property, Plant and Equipment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.50 0.47 0.44 0.40 0.37
SLXN
13GF Score
Silexion Therapeutics Corp SLXN
Property, Plant and Equipment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Silexion Therapeutics Property, Plant and Equipment Calculation

Property, Plant and Equipment (PPE) are the fixed assets of the companyFixed assets are also known as non-current assets.

Property, plant, and equipment includes assets that will - in the normal course of business - neither be used up in the next year nor will become a part of any product sold to customers.

Some of the most common parts of property, plant, and equipment are:


Land
Buildings (and leasehold improvements)
Transportation equipment
Manufacturing equipment
Office equipment
Office furniture

Companies with lots of property, plant, and equipment often have special categories. For example, railroad property includes:


Track
Ties
Ballast
Bridges
Tunnels
Signals
Locomotives
Freight Cars

There is often a note in the financial statements - found in a company's 10-K - that will explain the different categories of property a company owns.

The market value of property, plant, and equipment can differ tremendously from the book value of property, plant, and equipment.

For example, when Berkshire Hathaway liquidated its textile mills, it had to pay the buyers of the company's manufacturing equipment to haul the equipment away. That property, plant, and equipment was literally worth less than zero. On the other hand, some companies own thousands of acres of land.

All property, plant, and equipment other than land is depreciated. Land is never depreciated. However, land is not marked up to market value either. Under Generally Accepted Accounting Principles (GAAP), land is shown on the balance sheet at cost.

The property, plant, and equipment line shown on the balance sheet is usually net property, plant, and equipment. This means it is the cost of the property, plant, and equipment less accumulated depreciation.

What does a Property, Plant and Equipment of $0.37 Mil mean?
Silexion Therapeutics (SLXN) has a Property, Plant and Equipment of $0.37 Mil as of Jun. 2026. The total property, plant and equipment recorded on a company's balance sheet less accumulated depreciation. View historical data on Silexion Therapeutics and its competitors.
Is Silexion Therapeutics' Property, Plant and Equipment too high?
Silexion Therapeutics' current Property, Plant and Equipment is $0.37 Mil. Overall, Silexion Therapeutics has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Silexion Therapeutics' Property, Plant and Equipment compare to DCOY and VRAX?
Silexion Therapeutics' Property, Plant and Equipment of $0.37 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Property, Plant and Equipment for a Biotechnology company?
A good Property, Plant and Equipment depends on the Biotechnology industry context. However, Property, Plant and Equipment should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Property, Plant and Equipment mean?
A high Property, Plant and Equipment can signal that a stock is expensive relative to its fundamentals. The total property, plant and equipment recorded on a company's balance sheet less accumulated depreciation. View historical data on Silexion Therapeutics and its competitors. Silexion Therapeutics's current Property, Plant and Equipment is $0.37 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Silexion Therapeutics stock overvalued right now?
Silexion Therapeutics (SLXN) has a current Property, Plant and Equipment of $0.37 Mil. The current Property, Plant and Equipment is $0.37 Mil. Silexion Therapeutics' overall GF Score™ is 13/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Property, Plant and Equipment calculated?
Property, Plant and Equipment is calculated from a company's financial statements. For Silexion Therapeutics (SLXN), the current Property, Plant and Equipment is $0.37 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Silexion Therapeutics Business Description

Address 12 Abba Hillel Road, Ramat-Gan, ISR, 5250606
Silexion Therapeutics Corp is a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for cancers driven by mutations in the mutations in the Kirsten rat sarcoma viral oncogene homolog (KRAS). Its proprietary technology is designed to prompt tumor cells to degrade the messenger RNA (mRNA) that bridges the oncogene and the cellular protein synthesis machinery, utilizing small interfering RNA (siRNA) constructs that are chemically modified to enhance stability and cellular uptake while maintaining biological activity that interferes with the mRNA function. Its product candidate, SIL204, is a second-generation siRNA engineered to suppress the production of mutated KRAS proteins.
13GF Score

Get the complete analysis for SLXN

Property, Plant and Equipment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.37
Price